Aurobindo Pharma Q1 Net Profit Up 61% on Strong Margins; Company on Track to Achieve FY25 Targets – Industry News

Aurobindo Pharma said its consolidated net profit rose 61 per cent year-on-year at Rs 919 crore in Q1 FY25, driven by strong sales across markets, compared to Rs 571 crore in Q1 FY24.

The Hyderabad-headquartered drugmaker’s operating revenue rose to Rs 7,567 crore in the June quarter as compared to Rs 6,851 crore in the same period in the previous year, the drugmaker said in a statement.

EBITDA before currency effects and other income stood at Rs 1,620 crore, representing a margin of 21.4%.

RK Swamy Ltd reports 11.4% revenue growth in Q1 FY25

Affle reports 27.8% revenue growth, 30.8% net profit growth in Q1 FY25

Emami Q1FY24 results: Profit rises 10.8% to Rs 152.64 crore on ‘exceptional performance’ of summer portfolio

Mankind Pharma to Acquire 100% of BSV; Plans to Expand High Barrier-to-Entry Portfolio

Aurobindo Pharma reported a 13.3% year-on-year growth in US revenues to Rs 3,555 crore, accounting for 47% of the company’s consolidated revenues. During the quarter, Aurobindo submitted eight abbreviated new drug applications (ANDAs) to the US Food and Drug Administration (FDA) and received final approval for ten ANDAs, including one for a specialty product.

As of June 30, 2024, the Company has submitted a total of 838 ANDAs to the FDA, receiving 668 final approvals and 26 tentative approvals. Aurobindo launched ten new products during the quarter, including one injectable.

Revenue from Europe increased 7.9% to Rs 1,982 crore, contributing 26.2% to consolidated revenue.

Meanwhile, revenue from growth markets formulas grew 49.2% to ₹709 crore, accounting for 9.4% of consolidated revenue. Domestic sales stood at ₹61 crore.

Commenting on the company’s performance, K. Nithyananda Reddy, Vice President and Managing Director, said, “We are pleased with our continued strong performance during the quarter, with significant revenue growth across our business segments. Our profitability was maintained on the back of improved gross margins and operating efficiencies, while ramping up our recently commercialized plants. We are confident of achieving our growth targets for fiscal 2025.”